Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Independent Janoshik verification with every order
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Long-Acting GLP-1 Analogue (Research)
A synthetic long-acting GLP-1 receptor agonist analogue. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Assayed by Janoshik to ≥99% purity — the certificate is included with every order.
Valtrax Research supplies materials strictly for in-vitro laboratory research. They are not drugs, supplements, cosmetics, or medical devices, and are not intended for human or animal use, ingestion, or administration. By ordering, you confirm you are a qualified researcher purchasing for lawful research use, in accordance with all applicable Canadian laws and regulations.
Semaglutide is a 31-residue analogue of glucagon-like peptide-1 (GLP-1), the gut incretin that ties nutrient intake to insulin release. A C-18 diacid chain plus two backbone substitutions give it albumin binding and resistance to DPP-4, so it persists far longer than native GLP-1. Valtrax ships it lyophilized, for laboratory use only.
In the literature it stands in as the reference long-acting GLP-1 agonist, used to probe receptor activation and metabolic endpoints in cell and animal models.
Semaglutide is studied as a stable GLP-1 receptor agonist: receptor engagement and cAMP signalling in vitro, glucose-dependent insulin secretion in beta-cell systems, and food-intake and weight endpoints in animal models. It frequently anchors comparisons against other incretin compounds.
Native GLP-1 clears in minutes; semaglutide lasts about a week — the engineering trade that made it a workhorse in incretin research. Bench studies track how it engages the GLP-1 receptor, drives cAMP and insulin-secretion readouts in beta-cell lines, and shifts food-intake and body-weight endpoints in rodent models.
Its published record runs from receptor pharmacology through large metabolic-outcome trials, so it is the usual comparator when newer GLP-1 and dual agonists are characterised.
GLP-1 was characterised during incretin physiology work in the 1980s, and its therapeutic flaw was clear immediately — it vanishes from circulation almost at once. A decade of analogue engineering followed, chasing stability and a workable half-life.
Semaglutide (Lau et al., 2015) was the once-weekly answer: a fatty-diacid linker for albumin binding plus an Aib substitution to block DPP-4. It became the yardstick for the GLP-1 and GLP-1/GIP agonists that followed.
Lau, J. et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.
PubMedMarso, S.P. et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).
PubMedWilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1).
PubMedKushner, R.F. et al. (2020). Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5.
PubMedThird-party tested for purity, identity, quantity.
Same Shelf
